Background: Chromosomal mutations that reduce ciprofloxacin susceptibility in Escherichia coli characteristically map to drug target genes (gyrAB and parCE), and genes encoding regulators of the AcrAB-TolC efflux pump. Mutations in RNA polymerase can also reduce susceptibility, by up-regulating the MdtK efflux pump.
Introduction
The antibacterial drug ciprofloxacin targets DNA gyrase and topoisomerase IV, inhibiting DNA synthesis 1, 2 and causing lethal double-stranded breaks in the chromosome. 3 Resistant isolates typically carry chromosomal mutations in some or all of the target genes, gyrA, gyrB, parC and parE, [4] [5] [6] often accompanied by mutations in marR, soxR and/or acrR 3,7-11 that increase expression of the AcrAB-TolC efflux pump, down-regulate the OmpF porin (an entry route for ciprofloxacin) and up-regulate the more restrictive OmpC porin. 6, 12, 13 In addition, several plasmid-borne genes can contribute to resistance in Escherichia coli. These include genes encoding different Qnr family proteins that protect the drug targets, [14] [15] [16] a gene encoding an amino-acetyl-transferase enzyme (aac-6 0 -Ib-cr) that inactivates the drug, 17 and genes encoding efflux pumps such as QepA 18, 19 or OqxAB. 16 Single mutations or acquired resistance genes increase MIC 2-fold (e.g. marR) or up to 24-fold (gyrA and qnr). 6, 20 The absence of individual genetic alterations that cause larger fold increases in MIC explains why the evolution of resistance to ciprofloxacin in E. coli requires the accumulation of multiple genetic alterations.
This multi-step evolution of resistance can result in very complex genotypes. In the absence of detailed knowledge of the evolutionary history and experimental tests, it is problematic to determine the complete set of genes and alleles that contribute to reduced susceptibility in an evolved resistant isolate. There are indications in the literature that alterations in additional, noncanonical genes might be involved in resistance evolution. [21] [22] [23] [24] Indeed, it was recently shown that mutations in rpoB, encoding a subunit of RNA polymerase, reduce susceptibility to ciprofloxacin by increasing expression of the MdtK inner membrane efflux pump. 25 Here we asked whether mutations in additional chromosomal genes in E. coli could contribute significantly to the evolution of resistance to ciprofloxacin. Our approach was to experimentally evolve E. coli to resistance, then use genome sequencing and genetic analysis to identify mutations in non-canonical genes that contributed to resistance. We found that mutations in aminoacyltRNA synthetase (aaRS) genes are selected by ciprofloxacin, and we report the mechanism by which mutations in leuS contribute to the resistance phenotype.
Materials and methods

Media and growth conditions
Strains (Table S1 , available as Supplementary data at JAC Online) were routinely grown in LB (10 g tryptone, 5 g yeast extract, 10 g NaCl per litre of water) or on LA (LB with the addition of 1.5% agar), with antibiotics or sucrose added as described in the text. Mueller-Hinton II medium (MHII) (Becton, Dickinson, France) was used for in vitro evolution, MIC measurements and antibiotic gradient plates.
In vitro evolution
From 10 independent cultures of CH1378 (E. coli MG1655 DmutS, ciprofloxacin MIC 0.016 mg/L) aliquots of 2%10 8 cfu were spread on MH agar with ciprofloxacin at 2, 4, 6, 8 and 10-fold MIC. After 48 h at 37 C, a single colony from each culture was picked from the highest drug concentration where growth occurred (defined as colonies of diameter 1 mm) and streak-purified three times on MHII agar at the selective concentration. Second-step mutants were selected in the same manner, by spreading onto plates with ciprofloxacin concentrations at 2, 4, 6, 8 and 10 times the mutant-selective concentration. Selections were continued for three or four cycles, until the selective concentration reached or exceeded 1 mg/L.
DNA sequencing
DNA for WGS prepared using a Genomic DNA Buffer Set (Qiagen, Sweden) was sent to Beijing Genomic Institute (BGI; Tai Po, Hong Kong) for library preparation and sequencing and analysed using CLC Genomic Workbench 6 (CLC Bio, Denmark). Local DNA sequencing was performed at the Macrogen Europe Laboratory (Amsterdam, Netherlands) and analysed using CLC Main Workbench 7.7.1.
RNA sequencing
Bacteria were grown in liquid culture to mid-log phase (OD 600 0.25-0.4), and 1.5 mL of each culture was mixed with 3 mL of RNAprotect Bacteria Reagent (Qiagen). RNA was isolated using an RNeasy Mini Kit (Qiagen) and DNase Turbo Free (Ambion, Life Technologies) was used to remove DNA. Purified RNA (4500 lg) from each sample (two biological replicates for each strain) was sent to BGI (Tai Po, Hong Kong) for transcriptome analysis.
qPCR
RNA was isolated in three biological replicates per strain, at OD 600 0.25-0.3, using the RNeasy Mini Kit (Qiagen). DNA was removed with the DNase Turbo Free (Ambion, Life Technologies) kit, and the High Capacity Reverse Transcription kit (Applied Biosystems) was used to generate cDNA. Quantifications of nucleotide concentrations were made using the Nanodrop NO-1000 spectrophotometer. The Eco Real-Time PCR System (Illumina) was used for qPCR, with 20 lL reactions containing 1 lL of diluted cDNA (dilutions 1:10, 1:100, 1:1000), 12.5 lL of PerfeCTa SYBR Green FastMix (Quanta Biosciences), 1.25 lL of 10 lM forward and reverse primers (Table S2 ) and 4 lL of ddH 2 O. Standard housekeeping genes were idnT, cysG and hcaT. 26 
Strain construction
Lambda red recombineering 27 was used to place selectable markers onto the chromosomes of bacterial strain CH1940 or CH3302 (Table S1 ). P1 bacteriophage was used to transduce selectable cassettes between strains. The kan-sacB cassette linked to leuS Asp162Asn and Ser496Pro was removed by P1 transduction with a lysate grown on a WT E. coli, selecting for sucrose-resistant recombinants on salt-free LA containing 5% sucrose. Drug cassettes bounded by Flp recombination target sequences (FRT) were removed by transformation of pCP20, expressing Flp enzyme, 28 with selection on ampicillin (100 mg/L), leaving an FRT scar at the site of insertion. Local sequencing confirmed all genetic constructs. Oligonucleotides for PCR, sequencing and recombineering are listed in Table S2 .
Growth rate measurements
Four biological replicates of liquid overnight cultures were diluted 1:1000 in LB media. Aliquots (300 lL/well) were pipetted into a Honeycomb 2 100-well plate (Oy Growth Curves AB Ltd, Finland), and growth was measured using a Bioscreen C (Oy Growth Curves AB Ltd, Finland) with readings at 600 nm every 5 min for 18 h at 37 C with continuous shaking. Negative controls were included to correct OD 600 values by subtraction. The natural logarithm of each OD 600 value was plotted against time, and the linear regression slope for 10 subsequent OD 600 readings was calculated. Doubling time (minutes) was calculated by dividing ln 2 by the value of the maximal slope.
MIC
MIC was determined using broth microdilution in MHII medium. Bacterial suspension (McFarland 0.5) in 0.9% NaCl, determined using a Sensititre TM Nephelometer (Oxoid AB), was diluted 1:100 in MHII broth. Aliquots of 50 lL were mixed with 50 lL of MHII broth containing serially diluted antibiotic in 96-well round-bottomed plates. Mixtures were incubated for 18 h at 37 C before visual reading. Each strain was measured in at least three biological replicates. For mupirocin, bacterial suspensions were prepared in MHII broth supplemented with 30 mg/L mupirocin.
Growth competition assays
For growth competition assays, strains carried a yellow fluorescent marker (SYFP, CH2037) or a dTomato fluorescent marker (dTomato, CH6016). Overnight cultures were mixed 1:1, with dye-swaps included, diluted 1:142 in 180 lL of LB, with or without ciprofloxacin, in a round-bottomed 96-well plate and grown overnight at 37 C at 900 rpm in a PHMP-4 Thermoshaker (Grant-Bio, Cambridge). For measurements, cultures were diluted 1:128 in 200 lL of PBS in a round-bottomed 96-well plate. Proportions of strains in each culture were determined using a magnetically activated cell sorter (MACSQuant V R VYB, Miltenyi Biotech, Germany) counting 10 4 cells. Ratios were measured at timepoints 0 and 24 h as the fraction dTomato-labelled cells divided by SYFP-labelled cells. Values plotted against time generated an exponential trend line for each competition. From the slope a selection coefficient for one of the competing strains was determined, representing the change relative to the competing strain expressed as percentage per generation. 29 
Antibiotic gradient plates
Antibiotic gradient plates were cast in tilted 12%12 cm dishes (Greiner BioOne, GmbH) with 50 mL of MHII agar supplemented with antibiotic at a set concentration. After solidifying (1.5 h at room temperature), 50 mL of MHII agar without antibiotic was poured on top (plates now lying flat) and left to solidify for at least 1.5 h. Colonies dispersed in 5 mL of 0.9% NaCl were diluted to 10 4 cfu/mL and 5 lL aliquots were spotted across the gradient.
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Plates were incubated at 37 C for 48 or 72 h. At least three independent measurements were made for each strain.
Results
Selection of novel resistant mutants
Resistance to ciprofloxacin was evolved in 10 independent lineages of E. coli K-12 mutS::Tn10. One endpoint strain from each lineage was subjected to WGS (Table S3 ). Genotypes were examined for mutations occurring independently in different lineages in genes not typically associated with resistance. Mutations in rpoB and rpoC were noted, in agreement with the recent finding that RNA polymerase mutations contribute to ciprofloxacin resistance. 25 Mutations were also noted in genes encoding aaRS enzymes in 5/10 lineages (Table S3) , with two independently selected in leuS (Asp162Asn and Ser496Pro), suggesting these might be associated with resistance to ciprofloxacin.
leuS mutations reduce susceptibility to ciprofloxacin
We asked whether the leuS mutations were involved in reducing susceptibility to ciprofloxacin. Repairing each leuS mutation in the complex evolved strains caused a 2-fold reduction in ciprofloxacin MIC (Table S4) . We next introduced each leuS mutation into several simple genetic backgrounds (Table 1) to test whether each was sufficient to reduce susceptibility. Ciprofloxacin MIC increased 2-to 4-fold in the presence of each leuS mutation in strains carrying gyrA Ser83Leu and/or DmarR DacrR resistance mutations (Table 1) and significantly increased competitive fitness as a function of increasing ciprofloxacin concentration ( Figure 1 ). No increase in MIC was observed in the fully susceptible WT. However, MIC is a relatively crude assay and might not detect subtle changes in susceptibility. To evaluate this we performed two tests. Growth competition (WT versus each isogenic leuS mutant) as a function of ciprofloxacin concentration showed an advantage for each leuS mutant ( Figure S1A , B). Growth on antibiotic gradient plates also showed that each leuS mutation reduced susceptibility to ciprofloxacin in an otherwise WT strain ( Figure S1C ). We conclude that the leuS mutations reduce susceptibility to ciprofloxacin in multiple genetic backgrounds.
We also performed a complementation assay for the leuS mutant with the stronger phenotype, Ser496Pro, to determine whether expression of a WT leuS gene would reduce the resistance phenotype. We constructed strains with a WT leuS gene expressed under the control of the arabinose promoter (pBAD) on the chromosome, and also carrying either WT leuS or leuS Ser496Pro at its native location. Expressing the leuS ! gene with arabinose induction reduced ciprofloxacin resistance in the leuS Ser496Pro strain, measured both in MIC assays and as growth on antibiotic gradient plates ( Figure S2 ). In contrast, overexpression of leuS ! in the WT background did not affect ciprofloxacin susceptibility. These experiments provide strong additional evidence that the leuS mutation is involved in reducing ciprofloxacin susceptibility, and furthermore indicate that the phenotype of the mutation is due to a reduced functionality of the synthetase.
leuS mutations alter global transcription patterns
We hypothesized that aaRS mutations might influence ciprofloxacin susceptibility indirectly by triggering a stringent response, resulting in global alterations in gene expression. 30 RNA sequencing showed that both leuS alleles had similar, large impacts on global mRNA levels (Tables S5 and S6) , with leuS Ser496Pro affecting 200 more genes than leuS Asp162Asn, and causing a larger fold change in transcript level (2.1-fold greater, P , 0.01) (Figure 2a) . The overall pattern of changes was strikingly similar to that associated with the onset of a stringent response, with 90% of genes previously found to be up-regulated in a microarray-based analysis of E. coli MG1655 31 also being up-regulated by the presence of the leuS mutations. To test this similarity to a stringent response we deleted relA in strains carrying the leuS mutations and found that this reversed the MIC increase associated with the leuS mutations ( Table S1 ), showing that the reduced susceptibility is RelA dependent. We also treated LM709 (leuS WT) with 30 mg/L mupirocin, an antibiotic that inhibits the isoleucine tRNA synthetase (ileRS) and thus induces ppGpp production in E. coli, 32 and found this increased the ciprofloxacin MIC 2-fold. Together, these data show that inhibition of aaRS enzymes, either by chemical inhibition (mupirocin) or by mutation (leuS mutations), reduces susceptibility to ciprofloxacin by inducing a stringent-like transcriptional response. (Tables S5 and S6 ) were several that could plausibly be associated with affecting susceptibility to ciprofloxacin: (i) mdtK, encoding an inner membrane efflux pump for which increased transcription reduces susceptibility to ciprofloxacin; 25 (ii) acrZ, a component of the AcrAB-TolC efflux pump possibly involved in determining substrate specificity; 33, 34 (iii) ydhIJK, a putative efflux pump operon; 35 and (iv) ompF, encoding an outer membrane protein that favours ciprofloxacin influx. 36 We hypothesized that increases in the levels of these and possibly other transcripts play a role in reducing susceptibility to ciprofloxacin. We tested the significance of the RNA sequencing results by performing qPCR to measure transcript levels of the three genes mdtK, acrZ and ydhIJK. These measurements were made on strains carrying the two different leuS mutants, on a leuS WT control strain (LM709), and on the corresponding isogenic DrelA mutants. LM709 was used as a relative reference point for the transcript levels of mdtK, acrZ and ydhIJK. The results showed that a DrelA mutation in an leuS WT background has no effect on the expression levels of mdtK, acrZ or ydhIJK. In contrast, the levels of mdtK and ydhIJK were found to increase in strains carrying either of the leuS mutations, and this increase was dependent on having an active relA gene in the leuS mutant strains ( Figure S3 ). Changes in level were not significant for acrZ. In summary, we were able to show for two of the three genes implicated in leuS-mediated resistance, mdtK and ydhIJK, that transcription levels were increased in leuS mutant strains, and that the increase was dependent on an active relA gene.
To test whether expression of mdtK, acrZ and ydhIJK influences ciprofloxacin susceptibility we constructed isogenic strains with these loci deleted, individually and in combination (Table S1 ) and measured MIC and growth competition as a function of ciprofloxacin concentration. Single-and double-deletion mutants had relatively small or insignificant effects on MIC (Table S1 ) but the triple deletion DmdtK DacrZ DydhIJK caused a large reduction specifically associated with leuS mutations (Asp162Asn, 8-fold reduction; Ser496Pro, 20-fold reduction) with no significant change when leuS was WT (Table S1 ). The surprisingly large reduction in MIC in the triple-pump deletion leuS strains is probably due to increased ciprofloxacin influx mediated by increased expression of ompF.
Indeed, when we deleted ompF from the DmdtK DacrZ DydhIJK strains the MIC increased in the leuS mutants, from 0.375 to 1.5 mg/L (leuS Asp162Asn), and from 0.19 to 3 mg/L (leuS Ser496Pro) (Table S1 ). The growth competition assays were in broad agreement with MIC data, with single-and double-pump loci deletions having minor or allele-specific effects on competitive ability ( Figure S4 ), whereas the triple deletion abolished the competitive ability of each leuS mutant strain but had no significant impact on the leuS WT strain (Figure 2b ). These data show that reduced susceptibility of the leuS mutant strains is strongly dependent on the activities of the mdtK acrZ and ydhIJK efflux pump loci.
Mutations in leuS reduce susceptibility to other classes of antibiotics
We asked whether leuS mutations decreased susceptibility to antibiotic classes other than ciprofloxacin. Using antibiotic gradient plates and MIC measurements, we assayed the influence of leuS mutations on susceptibility to gentamicin, tetracycline, rifampicin, chloramphenicol, mecillinam, ampicillin and trimethoprim. The assays demonstrated reduced susceptibility to rifampicin, chloramphenicol, mecillinam, ampicillin and trimethoprim, showing that both leuS mutations reduce susceptibility to diverse classes of antibiotics ( Figure 3 , Figure S5 and Table S7 ). For several of these antibiotics the reduction in susceptibility associated with the leuS mutations was partly or completely reversed in DrelA strains (rifampicin, mecillinam, ampicillin and trimethoprim) or DmdtK DacrZ DydhIJK strains (mecillinam, ampicillin, trimethoprim and chloramphenicol). These data show that the mechanism by which leuS mutations reduce susceptibility to ciprofloxacin also acts to reduce susceptibility to antibiotics of different classes ( Figure S6 and Table S7 panels B, C).
Mutations in additional tRNA synthetases reduce susceptibility to ciprofloxacin
We asked whether the phenotype of reduced susceptibility to ciprofloxacin was specific to these two leuS mutations. Mutations in additional aaRS genes, tyrS, aspS and pheS, were observed in the Garoff et al.
original in vitro evolution experiment (Table S3 ). In separate evolution experiments carried out in mutS ! E. coli strains, we selected additional aaRS mutations (leuS Leu41His, aspS Asp207Ala, thrS His244Pro and thrS Ile582Ser). We constructed isogenic strains carrying leuS Leu41His, aspS Asp207Ala, thrS His244Pro, thrS Ile582Ser and pheS Thr110Ala. Resistance to bacteriophage P1 in some evolved strains prevented a similar reconstruction of the remaining two aaRS mutation in tyrS and aspS. Strains carrying seven different aaRS mutations (including leuS Asp162Asn and leuS Ser496Pro) were then tested for their ability to grow on antibiotic gradient agar plates. With the exception of pheS Thr110Ala, each of the other six aaRS mutations (leuS Asp162Asn, leuS Ser496Pro, leuS Leu41His, aspS Asp207Ala, thrS His244Pro and thrS Ile582Ser) significantly reduced susceptibility to ciprofloxacin (Figure 4 and Figure S7 ), and also caused an increase in ciprofloxacin MIC (Table S1 ). Interestingly, whereas the reduced susceptibility caused by the leuS and aspS mutations is at least partly dependent on RelA activity, the thrS mutations did not show a dependence on relA (Figure 4 , Figure S7 and Table S1 ), suggesting that they may operate through a different mechanism. We conclude that mutations in several different aaRS genes can reduce susceptibility to ciprofloxacin.
Discussion
Here we have shown that mutations in different aaRS genes (leuS, aspS and thrS) can reduce susceptibility to ciprofloxacin (Figures 1  and 4) . Focusing on two different mutations in leuS (Asp162Asn and Ser496Pro), we showed that this phenotype was RelA dependent and involved changes in global gene expression, similar to those induced by the stringent response, including up-regulation of several efflux pump genes whose activity we showed to be required for reduced susceptibility (Figures 2 and 4) . Each of the leuS mutations also reduced susceptibility to additional classes of antibiotics: rifampicin, chloramphenicol, mecillinam, ampicillin and trimethoprim (Figure 3 ). Taken together, these results show that aaRS genes could represent a large genetic target capable of generating mutations that reduce susceptibility to fluoroquinolones Figure S5 , and MIC values can be read in Table S7 . GEN, gentamicin; TET, tetracycline; RIF, rifampicin; CHL, chloramphenicol; MEC, mecillinam; AMP, ampicillin; TMP, trimethoprim.
aaRS mutations reduce antibiotic susceptibility JAC and other antibiotics. The current data argue that, at least for the leuS mutations, the reduced susceptibility to ciprofloxacin is mediated through up-regulation of drug efflux genes (Figure 2 and Figure S4 ).
The aaRS mutations occur in both classes of aaRS enzymes: LeuS belonging to class I, and AspS and ThrS belonging to class II. In a genetic complementation assay we found that expression of the WT leuS gene suppressed the resistance phenotype associated with the leuS Ser496Pro mutation ( Figure S2 ). This is consistent with the mutation causing antibiotic resistance by reducing aaRS function. With one exception, all of the selected aaRS mutations are located in the catalytic regions of their respective enzymes (leuS Leu41His, leuS Ser496Pro, aspS Asp207Ala, thrS His244Pro and thrS Ile582Ser). [37] [38] [39] [40] The only exception, leuS Asp162Asn, is situated in the zinc-binding region of the protein, important for positioning the tRNA acceptor arm. 40 The locations of the mutations are consistent with reduced enzymatic functionality being the cause of the resistance phenotype. This is also consistent with the increased resistance to ciprofloxacin we observed in the presence of mupirocin, which chemically inhibits ileRS functionality (see the Results section). Together, the data suggest that aaRS genes represent a large target where the occurrence of mutations reducing functionality has the potential to affect drug susceptibility.
There are previous reports linking mutations in aaRS genes, or induction of a stringent response, with reduced susceptibility to antimicrobial drugs. Mutations conferring resistance to mecillinam have been selected in alaS, argS, aspS and thrS, 41, 42 and for novobiocin in ileS, alaS, argS and leuS, 43 where the mutations were also shown to confer cross-resistance to mecillinam. 43 In the case of alaS and argS mutations, the mecillinam/novobiocin resistance phenotype was shown to be RelA dependent. 42, 43 Although the mechanism of mutational resistance to mecillinam is not known in detail, it was shown by deletion analysis that it makes PBP2, the target of mecillinam, dispensable for cell growth. 44 Induction of the stringent response has also been shown to reduce susceptibility to penicillins 45 and to trimethoprim in E. coli. 46 Interestingly, increased expression of mdtK has been reported to increase MICs of trimethoprim and chloramphenicol in E. coli. 47 Accordingly, although the earlier literature showed that mutations in aaRS genes, via induction of a stringent response, reduce susceptibility to mecillinam/penicillins and novobiocin, it did not provide any specific mechanism by which the resistance phenotype was mediated. Here, we have shown that mutations in aaRS genes reduce susceptibility to the clinically important fluoroquinolones, that the ciprofloxacin resistance phenotype of mutations selected in leuS is RelA dependent, and that the phenotype depends on the activity of the efflux-related genes mdtK, acrZ and ydhIJK. The current work does not rule out that other gene products affected by the aaRS mutations might also play a role in the observed net reduction in susceptibility.
Whereas the reduction in ciprofloxacin susceptibility associated with leuS and aspS mutations is RelA dependent (Figure 4 and Table S1 ), mutations selected for the same phenotype in thrS are unaffected by deletion of relA ( Figure 4 and Table S1 ). Interestingly, in a study of LpxC inhibitors (LpxC is an essential enzyme involved in lipid A synthesis), a resistance mutation selected in thrS (Ser517Ala) was found to increase the MIC of ciprofloxacin 2-fold. 48 This thrS mutation reduced protein synthesis and growth rates, which the authors suggested might be the cause of reduced susceptibility to ciprofloxacin. The possibility that the rate of protein synthesis might influence susceptibility to fluoroquinolones is supported by evidence that pre-treatment of E. coli with chloramphenicol, a protein synthesis inhibitor, reduces killing by fluoroquinolones. 49 This raises the possibility that the thrS mutations operate through a mechanism involving a direct effect on protein synthesis, but this remains to be elucidated in future studies.
Whereas the effect of the leuS mutations is significant in the fully susceptible WT genetic background ( Figure S1 ), it is magnified in the gyrA Ser83Leu DmarR DacrR genetic background ( Table 1) . The mechanism of resistance we have identified (Figure 2b) suggests a possible explanation for this observation. Increased expression of inner membrane pumps would remove some of the ciprofloxacin from the cytoplasm to the periplasm, from where it could either be pumped out of the cell (for example by AcrAB-TolC) or diffuse back into the cytoplasm. It is plausible that the combined effects of reduced affinity for the drug target and multiple efflux pumps acting on different cellular compartments provide a significant boost to the net removal of ciprofloxacin from the cell. The influence of overall genotype on phenotype was also seen in the large differences in relative fitness costs associated with leuS mutations in different genetic backgrounds (Asp162Asn, 17%-29%; Ser496Pro, 18%-48%; Table 1 and Table S4 ), suggesting that there could also be a complex interplay between genotype and phenotype in resistant clinical isolates. One could argue that Figure S7 , and MIC values can be read in Table S1. fitness costs of this magnitude would preclude any clinical relevance for aaRS mutations. However, mutations that in the laboratory have fitness costs up to 20%, 20 such as those that up-regulate drug efflux, are found in clinical isolates. 7, 8 Accordingly, the influence of genotype on phenotype (concerning both susceptibility and fitness) makes it difficult to predict whether aaRS mutations contribute to the evolution of resistance in clinical isolates. We have searched WGS data on clinical isolates 8, [50] [51] [52] [53] for genetic variations in aaRS genes. We observed many SNPs predicted to cause amino acid substitutions, including several in close proximity to the aaRS mutations described in this study, but none that was identical. This shows a tolerance for variation in aaRS genes in clinical isolates, but determining whether particular aaRS variants have been selected to reduce susceptibility is non-trivial because information on the ancestry and evolutionary trajectories of clinical isolates is incomplete. However, given the association between the mutations described in this report and the induction of a stringent response, one could hypothesize that any mutation or condition that induced a stringent response would make bacteria in a clinical setting less susceptible to killing by fluoroquinolones. Interestingly, ciprofloxacin-resistant mutants with up-regulated expression of mdtK, one of the genes influenced by the leuS mutations, are found in clinical isolates, although the genetic basis for the upregulation is currently not known. 11 The results of this study open up the possibility that a novel, and relatively large, genetic target could contribute to the evolution of resistance to ciprofloxacin, and other antibiotic classes.
